Gillian L Schauer1, Rashid Njai2, Althea M Grant-Lenzy2. 1. CDC Foundation, Atlanta, GA, United States; Department of Health Services, School of Public Health, University of Washington, Seattle, WA, United States. Electronic address: gschauer@cdc.gov. 2. Office of the Deputy Director for Non-Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Abstract
BACKGROUND: The prevalence of modes of marijuana use (e.g., smoked, vaped, eaten, dabbed, etc.), and of multi-modal use has not been assessed across multiple states, and can inform marijuana prevention and education work, given that certain modes of use are associated with specific public health risks. This study aimed to assess the prevalence of different modalities of reported marijuana use among adults in 12 states. METHODS: Data came from 6174 adult marijuana users age 18 and older who responded to questions about past month and mode of marijuana use on the 2016 BRFSS surveys in 12 states with varied state marijuana policies. We used weighted frequencies for descriptive analyses, and logistic regression to identify correlates of multi-modal use. RESULTS: The prevalence of past month (current) marijuana use among adults in these states was 9.1 % (males = 12.0 %, females= 6.3 %). Among current marijuana users, 33.7 % reported multiple methods of marijuana use, 90.1 % reported any marijuana smoking (e.g., joints, blunts, bongs, bowls), 58.3 % reported only smoking (no other modes of consumption), 24.5 % reported any edible use, 4.5 % reported using only edibles, 19.4 % reported any marijuana vaping, 2.1 % reported only vaping, 14.5 % reported any dabbing (flash vaporization/inhalation of highly concentrated marijuana), and 0.4 % reported only dabbing. Correlates of multimodal use are also examined. CONCLUSION: Multi-modal use of marijuana is common, and use of non-smoked marijuana (edibles, vaping, dabbing) often occurs in conjunction with other modes of marijuana use. Ongoing surveillance of marijuana modes of use and multi-modal use is warranted to inform public education and prevention.
BACKGROUND: The prevalence of modes of marijuana use (e.g., smoked, vaped, eaten, dabbed, etc.), and of multi-modal use has not been assessed across multiple states, and can inform marijuana prevention and education work, given that certain modes of use are associated with specific public health risks. This study aimed to assess the prevalence of different modalities of reported marijuana use among adults in 12 states. METHODS: Data came from 6174 adult marijuana users age 18 and older who responded to questions about past month and mode of marijuana use on the 2016 BRFSS surveys in 12 states with varied state marijuana policies. We used weighted frequencies for descriptive analyses, and logistic regression to identify correlates of multi-modal use. RESULTS: The prevalence of past month (current) marijuana use among adults in these states was 9.1 % (males = 12.0 %, females= 6.3 %). Among current marijuana users, 33.7 % reported multiple methods of marijuana use, 90.1 % reported any marijuana smoking (e.g., joints, blunts, bongs, bowls), 58.3 % reported only smoking (no other modes of consumption), 24.5 % reported any edible use, 4.5 % reported using only edibles, 19.4 % reported any marijuana vaping, 2.1 % reported only vaping, 14.5 % reported any dabbing (flash vaporization/inhalation of highly concentrated marijuana), and 0.4 % reported only dabbing. Correlates of multimodal use are also examined. CONCLUSION: Multi-modal use of marijuana is common, and use of non-smoked marijuana (edibles, vaping, dabbing) often occurs in conjunction with other modes of marijuana use. Ongoing surveillance of marijuana modes of use and multi-modal use is warranted to inform public education and prevention.
Authors: Deborah S Hasin; Jacob Borodovsky; Dvora Shmulewitz; Claire Walsh; Ofir Livne; Cara A Struble; Efrat Aharonovich; David S Fink; Alan Budney Journal: Drug Alcohol Depend Date: 2021-10-29 Impact factor: 4.492
Authors: Catherine F Moore; Catherine M Davis; Eric L Harvey; Michael A Taffe; Elise M Weerts Journal: Pharmacol Biochem Behav Date: 2021-01-23 Impact factor: 3.533
Authors: Jenny L Wiley; Daniel G Barrus; Charlotte E Farquhar; Timothy W Lefever; Thomas F Gamage Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2020-08-15 Impact factor: 5.067
Authors: P A Newcomb; M Ton; R C Malen; J L Heffner; J Labadie; A I Phipps; A N Burnett-Hartman Journal: Cancer Causes Control Date: 2021-07-14 Impact factor: 2.532